>
Organization
Vertex Pharmaceuticals, Inc.
Topic
All Topics
People
Find news about people
Alumni
Find news on alumni of any org
Industries
Find news on a particular market
Your Contacts
Find news on your contacts
Sign up for free daily alerts on this feed:
By pressing Sign Up, you agree to our Terms of Use, Privacy Policy, and the LexisNexis Terms & Conditions

Follow

Change Feed

News on Vertex Pharmaceuticals, Inc.

... The company is expected to complete work by the end of this year.Vertex contracts and global trade compliance vice-president Nydia Rosado said it is 'proud ...
... a strong pipeline of patients who may eventually start on the drug. Vertex Pharmaceuticals talked up a new drug in its pipeline targeting an inherited ...
... this week about progress in drug development is Jeffrey Leiden, CEO of Vertex Pharmaceu-ticals (above) and John Maraganore, the chief executive of Alnylam. When Dr. ...
... molecule therapeutics, today announced the expansion of its collaboration with Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX). Under the terms of the expanded agreement, X-Chem will apply ...
... Review of a Biologics License Application (BLA). In October 2018, CRISPR and Vertex announced the FDA acceptance of the Investigational New Drug application (IND) for ...
... appointment of Paul Meister to the Arbor Board of Directors. Earlier today, Vertex Pharmaceuticals and Arbor announced a multi-year strategic research collaboration (https://bit.ly/2F4I0Bs). "These are ...
... machine learning, genome sequencing, gene synthesis, and high-throughput screening that will augment Vertex's efforts to develop gene-editing approaches for the treatment of serious diseases. "Our ...
... of the conference webcast will be archived on the company's website. About Vertex Vertex is a global biotechnology company that invests in scientific innovation to ...
... a rare genetic illness that attacks the lungs and other organs. Boston-based Vertex Pharmaceuticals has introduced three drugs since 2012 that treat the underlying cause ...
... investor concerns over Alexion's ability to steer ahead of competition. Jeff Leiden, Vertex Pharmaceuticals Five years ago, Vertex scientists briefed me on the results of ...
Subscribe now for full coverage on Vertex Pharmaceuticals, Inc.
Start My Free Trial